Gene therapy for anastomotic stenosis after arterial reconstruction

动脉重建后吻合口狭窄的基因治疗

基本信息

  • 批准号:
    10671101
  • 负责人:
  • 金额:
    $ 2.05万
  • 依托单位:
  • 依托单位国家:
    日本
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
  • 财政年份:
    1998
  • 资助国家:
    日本
  • 起止时间:
    1998 至 1999
  • 项目状态:
    已结题

项目摘要

Since neointimal hyperplasia is known to be critical in formation of anastomotic stenosis after arterial bypass operation, the purposes of the present study were to establish the method of gene transfer into neointima and to determine the important factor(s) regulating cell cycle in neointimal formation. For the first purpose, we applied adenovirus vectors containing LacZ gene to neointima of rat carotid artery, which was induced by balloon injury, and found that more than 1x10ィイD19ィエD1 PFU/mL of virus vector promoted high efficiency transfer of LacZ gene to neointimal cells. Miyata et al administrated the gene of mutant platelet-derived growth factor receptor to the rat carotid neointimal cells by the above method, and showed a significant suppression of the neointimal proliferation. To study the role of cell cycle in neointimal formation, expression of retinoblastoma protein (Rb) in balloon-injured rat carotid artery was assessed by western blot analysis, since phosphorylation of Rb releases the E2F transcription factor from its binding to Rb, which is a critical event in cell cycle. At 1 day after balloon injury, band shift of Rb, which indicates phosphorylation of Rb, was observed. The phosphorylation of Rb, became to be maximal at 2 days after injury, when maximal cell replication was detected in arterial media. The expression of cyclin D in arterial wall was also observed after balloon injury, though the expression increased gradually by 14 days after injury, indicating a discrepancy between Rb phosphorylation and cyclin D expression. Meanwhile, p27, cell cycle inhibitor, was expressed in uninjured arterial wall. The expression of p27 was down-regulated once immediately after injury but increased again from 7 days after injury These results suggested that p27 suppressed cyclin D after- day 7 and regulated phosphorylation of Rb of injured arterial cells.
鉴于动脉搭桥术后吻合口狭窄的形成与新生内膜的增殖密切相关,本研究旨在建立血管内膜基因转移的方法,并探讨细胞周期调控因子S在新生内膜形成中的作用。首先,我们将含有LacZ基因的重组腺病毒载体应用于球囊损伤诱导的大鼠颈动脉新生内膜,发现1×10ィイD19ィエD1pfu/mL腺病毒载体可促进LacZ基因高效转移至新生内膜细胞。Miyata等人通过上述方法将突变的血小板衍生生长因子受体基因导入大鼠颈动脉新生内膜细胞,并显示出明显的抑制新生内膜增殖的作用。为了研究细胞周期在新生内膜形成中的作用,用免疫印迹法检测了大鼠颈动脉球囊损伤后视网膜母细胞瘤蛋白(Rb)的表达,因为Rb的磷酸化使E2F转录因子从与Rb的结合中释放出来,这是细胞周期中的一个关键事件。球囊损伤后1d,Rb的条带发生移动,表明Rb的磷酸化。Rb的磷酸化在伤后2天达到最大,此时动脉中膜细胞复制最强。球囊损伤后动脉壁也有细胞周期蛋白D的表达,但14d后表达逐渐增加,提示Rb磷酸化与细胞周期蛋白D的表达存在差异。同时,细胞周期抑制因子p27在未损伤的动脉壁有表达。伤后即刻,p27的表达一度下调,7d后又开始升高,提示p27在伤后7d抑制细胞周期蛋白D的表达,并调节Rb的磷酸化。

项目成果

期刊论文数量(7)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
H. Koyama, et al.: "Cell signaling in injured rat arteries"Thrombosis and Haemostasis. 82. 806-809 (1999)
H. Koyama 等人:“受伤大鼠动脉中的细胞信号传导”血栓形成和止血。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
J. Deguchi et al: "Targeting endogenous platelet-derived growth factor B-chain by adenovirus-mediated gene transfer potently inhibits in vivo smooth muscle proliferation after arterial injury."Gene therapy. 6. 956-965 (1999)
J. Deguchi 等人:“通过腺病毒介导的基因转移靶向内源性血小板衍生生长因子 B 链,可有效抑制动脉损伤后的体内平滑肌增殖。”基因治疗。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
出口 順夫: "バルーン障害後再狭窄に対するPDGF-Bを標的とした治療の可能性"脈管学. 38. 813-816 (1998)
Juno Deguchi:“针对球囊损伤后再狭窄的治疗的可能性”血管学 38. 813-816 (1998)。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
J. Deguchi, et al.: "Targeting endogenous platelet-derived growth factor B chain by adenovirus-mediated gene transfer potently inhibits in vivo ..."Gene Therapy. 6. 956-965 (1999)
J. Deguchi 等人:“通过腺病毒介导的基因转移靶向内源性血小板衍生生长因子 B 链,可有效抑制体内……”基因治疗。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
J. Deguchi: "Targeting endogenous platelet-derived growth factorB-chain by adenovirus-mediated gene transfer potently inhibits・・・・・"Gene therapy. 6. 956-965 (1999)
J. Deguchi:“通过腺病毒介导的基因转移靶向内源性血小板衍生生长因子 B 链可有效抑制……”基因治疗。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

OSHIRO Hidemi其他文献

OSHIRO Hidemi的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('OSHIRO Hidemi', 18)}}的其他基金

Gene transfer of angiogenic growth factor for treatment of chronic limb ischemia
血管生成生长因子的基因转移治疗慢性肢体缺血
  • 批准号:
    10671103
  • 财政年份:
    1998
  • 资助金额:
    $ 2.05万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)

相似海外基金

ICF: A novel dual-target gene therapy for safe and efficacious treatment of chronic non-infectious uveitis
ICF:一种安全有效治疗慢性非感染性葡萄膜炎的新型双靶点基因疗法
  • 批准号:
    MR/Z50385X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 2.05万
  • 项目类别:
    Research Grant
Next-generation automation and PAT implementation for QbD and enhanced approaches for cell and gene therapy
QbD 的下一代自动化和 PAT 实施以及细胞和基因治疗的增强方法
  • 批准号:
    10087446
  • 财政年份:
    2024
  • 资助金额:
    $ 2.05万
  • 项目类别:
    Collaborative R&D
Longitudinal structural and cognitive functional imaging and outcome prediction in focal epilepsy treated with gene therapy and surgical resection.
基因治疗和手术切除治疗局灶性癫痫的纵向结构和认知功能成像及结果预测。
  • 批准号:
    MR/X031039/1
  • 财政年份:
    2024
  • 资助金额:
    $ 2.05万
  • 项目类别:
    Research Grant
GeneT: The Gene Therapy CoE at the Center of Portugal
GeneT:葡萄牙中心的基因治疗 CoE
  • 批准号:
    10090933
  • 财政年份:
    2024
  • 资助金额:
    $ 2.05万
  • 项目类别:
    EU-Funded
Phase I/II clinical trial of autologous T cell gene therapy to treat X-linked lymphoproliferative disease (XLP)
自体T细胞基因疗法治疗X连锁淋巴增殖性疾病(XLP)的I/II期临床试验
  • 批准号:
    MR/Y019458/1
  • 财政年份:
    2024
  • 资助金额:
    $ 2.05万
  • 项目类别:
    Research Grant
SBIR Phase I: Development of an Adjustable Gene Therapy Platform Technology
SBIR 第一阶段:可调节基因治疗平台技术的开发
  • 批准号:
    2240683
  • 财政年份:
    2023
  • 资助金额:
    $ 2.05万
  • 项目类别:
    Standard Grant
Exploration novel effects of SHED-TK-derived exosomes on TK/GCV suicide gene therapy
探索SHED-TK衍生的外泌体对TK/GCV自杀基因治疗的新作用
  • 批准号:
    23K15643
  • 财政年份:
    2023
  • 资助金额:
    $ 2.05万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Gene expression profiling of skin ulcers for short-acting in vivo gene therapy
皮肤溃疡的基因表达谱用于短效体内基因治疗
  • 批准号:
    23K19673
  • 财政年份:
    2023
  • 资助金额:
    $ 2.05万
  • 项目类别:
    Grant-in-Aid for Research Activity Start-up
Activation of long non-coding RNA by a gene therapy CRISPR/Cas9 approach to prevent vein graft failure
通过基因治疗 CRISPR/Cas9 方法激活长非编码 RNA 以预防静脉移植失败
  • 批准号:
    EP/X024563/1
  • 财政年份:
    2023
  • 资助金额:
    $ 2.05万
  • 项目类别:
    Research Grant
Developing a gene therapy product to treat pressure ulcers in lower-limb amputees
开发一种基因治疗产品来治疗下肢截肢者的压力性溃疡
  • 批准号:
    2888189
  • 财政年份:
    2023
  • 资助金额:
    $ 2.05万
  • 项目类别:
    Studentship
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了